Form 4: Corvus Pharma Grants 400,000 Stock Options to SVP

Corvus Pharmaceuticals, Inc. granted 400,000 stock options to William Benton Jones, SVP of Pharmaceutical Development, with an exercise price of $8.81 per share.

Summary

• William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, Inc. (CRVS), was granted 400,000 stock options.
• The options have an exercise price of $8.81 per share.
• The grant date for these options is December 4, 2025.
• The options will vest over 36 months, with 1/36th of the shares becoming exercisable each month from December 4, 2025, contingent on Mr. Jones's continued employment.
• The options expire on December 4, 2035.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally positive for executive retention and alignment of interests, but has a minor dilutive potential. It's a neutral to slightly positive event.

Positives

• The grant of stock options serves as an incentive for the SVP of Pharmaceutical Development, William Benton Jones, aligning his interests with long-term shareholder value creation.
• It demonstrates the company's commitment to retaining and motivating key executive talent.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, although this is a standard aspect of equity compensation.

Risks

• Future dilution of existing shareholders if the 400,000 options are exercised.
• The value of the options is tied to the company's stock performance, meaning the incentive may not materialize if the stock price does not increase above the exercise price.

Future Outlook

The stock options are designed to incentivize the SVP over a multi-year period, with vesting occurring monthly over 36 months from December 4, 2025, contingent on continued service. This indicates a long-term retention strategy for a key executive.

Industry Context

Granting stock options to senior executives is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key talent, particularly in roles critical to drug development like Pharmaceutical Development. This aligns executive incentives with the long-term success and stock performance of the company, which is crucial in an industry with long development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of 400,000 stock options to a Senior Vice President is a standard form of equity compensation in the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use stock options and restricted stock units to incentivize executives.
• A 10-year expiration period (until 2035) is typical for employee stock options, providing a long-term incentive horizon.
• The 3-year monthly vesting schedule (1/36th per month) is also a common industry standard for executive retention and performance alignment, similar to vesting schedules seen at companies such as Amgen or Pfizer for their senior leadership.

Related Party Transactions

• The grant of 400,000 stock options to William Benton Jones, SVP of Pharmaceutical Development, constitutes a related party transaction as he is an officer of the issuer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize the executive to drive company growth and stock price appreciation.
• Employees: May signal a stable and incentivized leadership team, potentially boosting morale.
• Management: William Benton Jones is directly incentivized to increase the company's stock price above $8.81 and remain with the company for the 36-month vesting period.

Next Steps

• The granted stock options will begin vesting on December 4, 2025, at a rate of 1/36th per month.
• William Benton Jones must continue his service relationship with Corvus Pharmaceuticals, Inc. to receive the vested shares.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Executive Compensation, Form 4, Insider Transaction, Pharmaceutical Development, Equity Grant, William Benton Jones